Hyperbilirubinemia type 1
Hyperbilirubinemia Type 1, also known as Crigler-Najjar syndrome Type 1, is a rare genetic disorder characterized by the body's inability to properly process bilirubin, a yellow compound that is formed by the breakdown of red blood cells. This condition leads to an excessive accumulation of bilirubin in the blood, resulting in jaundice (yellowing of the skin and eyes). Hyperbilirubinemia Type 1 is an autosomal recessive disorder, meaning that an individual must inherit two defective genes, one from each parent, to be affected.
Causes
Hyperbilirubinemia Type 1 is caused by mutations in the UGT1A1 gene, which encodes the enzyme uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). This enzyme plays a critical role in the conversion of bilirubin into a form that can be eliminated from the body through bile. Mutations in the UGT1A1 gene result in reduced or absent activity of this enzyme, leading to the accumulation of unconjugated bilirubin in the blood.
Symptoms
The primary symptom of Hyperbilirubinemia Type 1 is persistent jaundice, which can appear shortly after birth. Unlike physiological jaundice, which is common in newborns and resolves without treatment, the jaundice associated with Hyperbilirubinemia Type 1 persists and can lead to severe complications. High levels of unconjugated bilirubin can be toxic to the brain, a condition known as kernicterus, which can result in permanent neurological damage.
Diagnosis
Diagnosis of Hyperbilirubinemia Type 1 typically involves measuring the levels of bilirubin in the blood, with a particular focus on the unconjugated (indirect) bilirubin levels. Genetic testing can confirm mutations in the UGT1A1 gene, providing a definitive diagnosis.
Treatment
Treatment for Hyperbilirubinemia Type 1 is aimed at reducing the levels of bilirubin in the blood to prevent kernicterus. Treatment options include phototherapy, where the skin is exposed to specific types of light that help break down bilirubin; and plasmapheresis, a procedure that filters the blood to remove bilirubin. In severe cases, a liver transplant may be considered as a curative treatment.
Prognosis
The prognosis for individuals with Hyperbilirubinemia Type 1 varies. With early and aggressive treatment, the risk of brain damage and other complications can be minimized. However, the condition requires lifelong management, and individuals with Hyperbilirubinemia Type 1 are at risk for developing bilirubin-induced neurological damage if their bilirubin levels are not adequately controlled.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD